<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075136</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00058375</org_study_id>
    <nct_id>NCT04075136</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy</brief_title>
  <official_title>OCTA-Directed PDT Triple Therapy for Treatment-Naïve Patients With Exudative Age-Related Macular Degeneration Versus Standard of Care Anti-VEGF(Anti-vascular Endothelial Growth Factor) Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optical Coherent Tomography Angiography (OCTA)-Directed PDT Triple Therapy for
      Treatment-Naïve Patients with Exudative Age-related Macular Degeneration (ARMD) versus
      Standard of Care Anti-VEGF Monotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 48 week, single center, randomized controlled clinical trial. Approximately
      150 subjects will be randomized into three separate arms. This study compares the efficacy of
      standard of care Lucentis (ranibizumab) monotherapy versus OCTA-Directed PDT Triple Therapy
      with Lucentis (ranibizumab), PDT with Visudyne (verteporfin), and Triescence (triamcinolone
      acetonide) in treatment-naïve patients with Exudative Age-Related Macular Degeneration.
      OCTA-Directed PDT Double Therapy with Lucentis (ranibizumab) and PDT with Visudyne
      (verteporfin) will also be tested to confirm the hypothesis that steroids are necessary.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subretinal exudation resolution</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of subretinal exudation resolution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of intraretinal exudation resolution</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of intraretinal exudation resolution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subretinal exudation resolution</measure>
    <time_frame>12 months</time_frame>
    <description>Subretinal exudation resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of intraretinal exudation resolution</measure>
    <time_frame>12 months</time_frame>
    <description>Intraretinal exudation resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>Baseline</time_frame>
    <description>Best corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>12 months</time_frame>
    <description>Best corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment effect</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Duration of treatment effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foveal thickness</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using Optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foveal thickness</measure>
    <time_frame>12 Months</time_frame>
    <description>Measured using Optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Exudative Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Arm A: Lucentis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A standard of care treatment of 0.05ml/0.5mg Lucentis given every 4 weeks for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Lucentis &amp; PDT Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Lucentis, PDT Laser and Triescense</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A one time treatment of 0.05ml/0.5mg Lucentis in combination with PDT laser administered at half-fluence and an intravitreal injection of 0.5ml-2mg Triescence at the time of PDT treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intravitreal injection 0.5 MG Per 0.05 ML Injection.</description>
    <arm_group_label>Arm A: Lucentis</arm_group_label>
    <arm_group_label>Arm B: Lucentis &amp; PDT Laser</arm_group_label>
    <arm_group_label>Arm C: Lucentis, PDT Laser and Triescense</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photodynamic laser treatment (PDT)</intervention_name>
    <description>PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.</description>
    <arm_group_label>Arm B: Lucentis &amp; PDT Laser</arm_group_label>
    <arm_group_label>Arm C: Lucentis, PDT Laser and Triescense</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>Intravitreal injection of 0.5ml-2mg</description>
    <arm_group_label>Arm C: Lucentis, PDT Laser and Triescense</arm_group_label>
    <other_name>Triesence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verteporfin</intervention_name>
    <description>Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.</description>
    <arm_group_label>Arm B: Lucentis &amp; PDT Laser</arm_group_label>
    <arm_group_label>Arm C: Lucentis, PDT Laser and Triescense</arm_group_label>
    <other_name>Visudyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to give written informed consent

          -  Willing and able to comply with all study procedures for the duration of the study.

          -  Presence of Exudative ARMD with evidence of choroidal neovascularization: type 1, 2,
             and/or 3 on spectral domain OCT, fluorescein angiography, indocyanine green angiogram
             and optical coherent tomography angiography

          -  Visual Acuity of 20/25 to 20/400 at screening and baseline visits using an
             autorefractor or Early Treatment Diabetic Retinopathy Study

          -  Intraocular pressure less than or equal to 25mmHG

          -  Females of childbearing potential that are willing to use medically acceptable methods
             of birth control.

        Exclusion Criteria:

          -  Exudation maculopathies without drusen

          -  Previous treatment with macular photocoagulation, anti-VEGF medication or PDT with
             Visudyne

          -  Myocardial infarction or cerebrovascular accident within the last 6 weeks

          -  Previous vitrectomy

          -  Optic neuropathy

          -  Diabetic retinopathy

          -  Traction maculopathies

          -  Allergies to fluorescein and indocyanine, dilating agents or anti-VEGF medications

          -  Have received previous treatment for ARMD

          -  Any uncontrolled condition or illness that in the opinion of the investigator makes
             the subject unsuitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Research Manager</last_name>
    <phone>336-716-3937</phone>
    <email>bgordy@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Nelson, MD</last_name>
    <phone>336-713-1680</phone>
    <email>mhnelson@wakehealth.edu</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular degeneration</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Triescense</keyword>
  <keyword>Photodynamic laser treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Results will updated once final analysis is complete.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

